Biogen Delves Deeper Into Biosimilars With Tocilizumab Partnership

Signs Agreement With China’s Bio-Thera Solutions Worth Over $30m

 
• By Dean Rudge

Biogen has broken new ground in its biosimilar endeavors, expanding beyond its partnership with its part-owned Samsung Bioepis company by agreeing a deal for rights to Bio-Thera Solutions’ BAT1806 biosimilar Actemra/RoActemra (tocilizumab) candidate.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Biogen has agreed to make an upfront payment of $30m to Bio-Thera Solutions, contingent upon Phase III data results • Source: Shutterstock

More from Biosimilars

More from Products